

**Jeffrey Dunn, MD, FAAN**  
Stanford University | Stanford Medicine  
300 Pasteur Drive, Stanford, CA 94305  
Work: 650 736-4310; Fax: 650 725-7459  
2026

**Academic Appointments:**

2022-present Lily Sarafan Director of Neuroimmunology,  
Neurology & Neurological Sciences, Stanford University; Stanford, CA  
2013-present Clinical Professor of Neurology,  
Neurology & Neurological Sciences; Stanford University; Stanford, CA  
2008-2012 Clinical Associate Professor of Neurology,  
Neurology and Neurological Sciences; Stanford University; Stanford, CA  
1997-2007 Clinical Assistant Professor of Neurology,  
Department of Neurology; University of Washington; Seattle, WA  
1993-1996 Clinical Instructor in Neurology,  
Medicine (Neurology); University of Washington; Seattle, WA  
1992-1993 Chief Resident in Neurology,  
Medicine (Neurology); University of Washington; Seattle, WA

**Education:**

1985-1989 Doctor of Medicine (M.D.),  
Temple University School of Medicine; Philadelphia, PA  
1984-1985 Research Associate in Molecular Immunology;  
Fox Chase Cancer Center; Philadelphia, PA  
1979-1983 Bachelor of Arts (B.A.), French Literature  
Haverford College; Haverford, PA  
1982 Institut d'Études Françaises; Avignon, France

**Postgraduate Training:**

1990-1993 Residency in Neurology  
University of Washington; Seattle, WA  
1989-1990 Internship in Medicine;  
Virginia Health Sciences EVMS Graduate School of Medicine; Norfolk, VA

**Licensure and Certification:**

2025-2028 Diplomate, American Board of Psychiatry & Neurology # 67128  
in compliance with standards for continuing certification. ABPN ID 141291  
2016-2024 Diplomate recertification; American Board of Psychiatry & Neurology; #40439  
2004-2014 Diplomate; American Board of Psychiatry & Neurology; # 40439

1990 Diplomat, National Board of Medical Examiners; # 379589  
 2007-2027 Physician and Surgeon, California State; License # G88167  
 1993-2008 Physician and Surgeon, Washington State; License # 28894  
 1992-2026 DEA Registration, Schedules 2, 2N, 3, 3N, 4, 5; # BD285276  
 2004-present Unique Physician Identification Number NPI # 1639123383  
 2023-present Controlled Substance Utilization Review & Evaluations System (CURES);  
 State of California Department of Justice: confirmation # 1404679  
 2005-present NIH Certified Principal Investigator for Research in Human Subjects  
 2016-present HIPAA Privacy for Clinical Researchers Certificate # 2349604  
 2013-present CITI Collaborative Institutional training Initiative; Stanford University  
 Human Subjects Research Protections Curriculum Completion Ref #18928151  
 2009-present Medical Research Investigators Certification; Stanford University  
 CITI Collaborative Institutional Training Initiative; # 1111159  
 30 Oct 2023 Sponsor-Investigator Research Training; IND/IDE # 29902  
 Spectrum: Stanford Center for Clinical & Translational Research and Education  
 19 Aug 2024 HIPAA/ Protecting Patient Privacy Certification: issued by STARS  
 18 Mar 2025 DOR-1130 Export Controls Overview for Research Administrators: Certificate # 434764  
 24 Mar 2025 Certificate, Classic RAVE EDC Essentials for Investigators; Medidata Academy

#### **Clinical Teaching Responsibilities:**

2016-present Neuroimmunology and Stanford MS Center Attending,  
 Stanford Neuroscience Health Center; Palo Alto, CA  
 2008-2016 Neuroimmunology and Stanford MS Center Attending,  
 Stanford 300 Pasteur Medical Campus; Stanford, CA  
 2008-2019 Neurology Clerkship Director,  
 Department of Neurology and Neurosciences; Stanford University  
 2011-2017 Founder & Fellowship Director, Clinical Neuroimmunology Fellowship  
 Department of Neurology and Neurosciences; Stanford University  
 2016-2018 Course Director, Annual Breakthroughs in Neurologic Therapies; San Francisco, CA  
 2008-2024 Inpatient Ward and Consult Attending  
 Stanford University Hospital and Clinics; Stanford, CA  
 2008-2012 Preceptor, Neurology Residents' Clinic  
 Stanford University Hospital and Clinics; Stanford, CA  
 2004-2008 Preceptor, Multiple Sclerosis Fellowship  
 University of Washington: MS Hub and Evergreen MS Center; Seattle, WA  
 2000-2004 Ward and Consult Attending,  
 Puget Sound Veterans' Affairs Hospital Medical Center (U of W); Seattle, WA

#### **Other Teaching Experience (last 5 years):**

2008-present Preceptor, MS and Neuroimmunology Clinic for Neurology residents  
 Department of Neurology and Neurosciences; Stanford University; Stanford, CA  
 2008-present Neuroimmunology faculty, Neurology Resident Morning Report  
 2008-present Core Neuroimmunology faculty, Neurology residency didactic series  
 2012-present Founder and attending specialist, Neurology Weekly Case Conference  
 2014-present Founder and attending specialist, Neuroimmunology Challenging Case Series  
 31 Jan 2024 Resident lecture: Treatment & Immunotherapy of Multiple Sclerosis  
 11-18 Dec 23 Stanford Hospital Inpatient Consult Attending

14 Aug 2023 How to Make a Diagnosis of Multiple Sclerosis. Stanford Neuroimmunology Conference, recorded for Resident Reference Library (RRR): Zoom

02 July 2023 Orientation lecture to onboarding Neurology residents: UMN Findings on Neuro Exam with video and demonstrations: 1:00-2:30 pm LKSC Rooms #205-206

28 June 2023 Morning report Attending Review of Neuroimmunology Case with Neurology residents

28 June 2023 Morning report Attending Review of Neuroimmunology Case with Neurology residents

24 May 2023 Morning Report Attending Review of Neuroimmunology Case with residents

12 April 2023 Invited lecture to Neurology residents: Approach to Transverse Myelitis

29 Mar 2023: Invited lecture to Neurology Residents: Approach to Optic Neuritis and its treatment

5-12 Dec 2022 Stanford Hospital Inpatient Consulting Attending

30 Oct 2022 Stanford 25 Bedside Symposium: "Pearls of the Neurologic Examination" LKSC

25 July 2022: Stanford Neuroimmunology Conference Lecture of basics: How to Make a Diagnosis of Multiple Sclerosis

02 July 2022 Introduction to the Neuro Exam: UMN signs; to Neurology residents: SOM

03 Nov 2021 DDX of transverse myelitis; morning report for Stanford Neurology housestaff

20 Oct 2021 Diseases of the spinal cord. Stanford Neurology residency didactics; CAM

13 Oct 2021 Disease modifying therapies in MS. Stanford Neurology residency didactics; CAM

08 Feb 2021 Professors' Rounds, morning report for Stanford housestaff: virtual

**Fellows/Clinical Neuroimmunology:** (year of fellowship training: present position)

2025-2027 Garrett Timmons, MD  
Clinical Fellow in Neuroimmunology,  
Department of Neurology & Neurological Sciences; Stanford Medicine

2024-2027 Jacob Loeffler, MD  
Clinician Scientist Research Fellow in Neuroimmunology,  
Instructor on Neuroimmunology 2025-2027  
Department of Neurology & Neurological Sciences; Stanford University

2023-2026 Danwei Wu, MD  
Clinician Scientist Research Fellow in Neuroimmunology 2023-2024  
Instructor in Neuroimmunology 2024-2026;;  
Department of Neurology & Neurological Sciences; Stanford University

2022-2024 Esther Nie, MD, PhD  
Medical Director in Neuroimmunology, Kyverna Therapeutics; Emeryville, CA

2021-2023 Neda Sattarnejhad, MD  
Sylvia Lawry Fellowship in Multiple Sclerosis & Clinical Neuroimmunology;  
Post-doctoral Fellow in Translational Immunology; Stanford University: 2023-present

2020-2022 Jamie McDonald, MD  
Sylvia Lawry Fellowship in Multiple Sclerosis & Clinical Neuroimmunology:  
Clinical Assistant Professor in Neurology, Stanford Medicine/TriValley;  
Palo Alto & Pleasanton, CA: September 2022-present

2019-2021 Elaine Su, MD  
Sylvia Lawry Fellowship in Multiple Sclerosis & Clinical Neuroimmunology:  
MS-Neuroimmunology Faculty, Kaiser Los Angeles, Los Angeles, CA: 2021-present

2018-2020 Nina Bozinov, MD  
Sylvia Lawry Fellowship in Multiple Sclerosis & Clinical Neuroimmunology;  
Director, Kootenai Multiple Sclerosis Center; Coeur d'Alene, ID: 2020-present

2017-2018 Aaron Carlson, MD  
Clinical Fellow in MS-Neuroimmunology; Stanford University 2017-2018  
Faculty, University of Colorado Health Systems; Aurora, CO: 2019-present

2016-2017 Luka Vlahovic, MD  
 Clinical Fellow in MS & Neuroimmunology, Stanford University 2016-2017  
 Multiple Sclerosis Specialist Attending, Providence Multiple Sclerosis Center;  
 Portland, Oregon: 2022-present  
 Clinical Assistant Professor, Multiple Sclerosis Clinic. Department of Neurology;  
 Creighton University Medical Center; Omaha, NE: 2017-2022

2015-2016 Lucas Kipp, MD  
 Clinical Fellow in MS & Neuroimmunology, Stanford University 2015-2016  
 Clinical Associate Professor, Fellowship Director, Division Education Chief;  
 Stanford University Multiple Sclerosis Center; 2016-present

2014-2015 Esther Melamed, MD, PhD  
 Research Fellow in Neuroimmunology, Stanford University; 2014-2015  
 Associate Professor of Neurology & Neuroimmunology; Dept. of Neurology;  
 MS Clinic Dell Seton Medical Center; Austin, TX: 2015-present

2012-2013 Alexandra Goodyear, MD, MS  
 Sylvia Lawry Fellowship in MS & Clinical Neuroimmunology 2012-2013;  
 Global Development Lead, Genentech: South San Francisco, present

#### **Hospital or Affiliated Administration and Committee Assignments:**

2008-present Chief, Division of Neuroimmunology,  
 Department of Neurology & Neurosciences; Stanford University; Stanford, CA

2025-present Member, Neurology & Neurological Sciences Mentorship & Sponsorship Committee

2020-present Member, Institute for Immunity, Transplantation & Infection; Stanford, CA

2022-present Organizing Committee, Stanford Autoimmune & Allergy Supergroup Institute for  
 Immunity, Transplantation and Infection (ITI): Stanford University

2008-2019 Neurology Clerkship Director,  
 Department of Neurology and Neurosciences; Stanford University

2009-2019 Education Committee Member,  
 Department of Neurology & Neurosciences; Stanford University; Stanford, CA

2008-2024 Residency Ranking and Selection Committee; Department of Neurology;  
 Stanford University; Stanford, CA

2016-2018 Course Director, *Breakthroughs in Neurologic Therapies* Annual Symposium;  
 Departments of Neurology & Neurosurgery: San Francisco, CA

2010-2018 Fellowship Director, Clinical Neuroimmunology Fellowship Program;  
 Stanford University Department of Neurology and Neurosciences; Stanford, CA

2009-2011 Steering Committee, Criterion Based Evaluation Initiative;  
 Stanford University School of Medicine; Stanford, CA

#### **National Committee Memberships:**

2025-present Reviewer, NIH/ NIAID for NIAID Clinical Trial Planning Grants including PAR-23-206  
 focusing on clinical trials for Multiple Sclerosis. Immunology Review Branch, Scientific  
 Review Program, Division of Extramural Activities: NIAID | NIH | DHHS

2025-present First Edition Mentor, ECTRIMS International Mentor Programme; European Committee  
 for Treatment & Research in Multiple Sclerosis: Basel, Switzerland

2022-2024 Grant Award Review Committee, National MS Society; New York, NY

2020-2022 John Dystel Award Review Committee, American Academy of Neurology

2018-2020 Chair, Multiple Sclerosis Section, American Academy of Neurology;  
 St. Paul, MN: by national-international member election

2018-2020 Member, National Medical Advisory Council National Multiple Sclerosis Society; New York, NY

2015-2019 Member, Association for University Professors of Neurology (AUPN)

2014-2016 Vice Chair, Multiple Sclerosis Section, American Academy of Neurology peer-elected from national membership; American Academy of Neurology AAN MS and CNS Inflammatory Disease Topic Work Group TWG; AAN

2014-2015 Chair, MS Education Workgroup, Multiple Sclerosis General Section

2011-2014 American Academy of Neurology; St. Paul, MN

2013-2014 ACP Clinical Effectiveness Study Network OPT-UP Members

2010-2014 Executive Committee, MS General Section Councilor American Academy of Neurology; peer elected 2010

2011-2013 ACP Repository Oversight Committee Accelerated Cure Project for MS; Waltham, MA

2008-2011 Member, American Academy of Neurology MS Education Task Force

2008-present Member, National Consortium of Multiple Sclerosis Centers (CMSC)

**Other Professional Positions held:**

2022-present Member, Stanford Autoimmune & Allergy Super Group (SAAS); Stanford

2020-present Member, Stanford Institute for Immunity, Transplantation and Infection; Stanford University, Stanford, CA

2019-present Affiliated Faculty, Wu Tsai Neurosciences Institute; Stanford University, Stanford, CA

2013-present Clinical Professor of Neurology, Department of Neurology & Neurosciences; Stanford University; Stanford, CA

2008-2013 Clinical Associate Professor of Neurology, Department of Neurology and Neurosciences; Stanford University

2004-2008 Co-Founder and Chief Medical Officer, MS Hub Medical Group and Evergreen MS Center; Seattle/Kirkland, WA

1996-2004 Founder and Medical Co-Director, Overlake Multiple Sclerosis Clinic; Bellevue, WA

1993-2004 Attending Neurologist with Special Interest in Clinical Neuroimmunology, Neurological Associates of WA; Bellevue/Kirkland, WA

**Professional Society Memberships:**

2008-present Fellow, American Academy of Neurology

2006-present Member, MS Section; American Academy of Neurology

2004-present Member, Consortium of Multiple Sclerosis Centers

2016-present Member, Stanford Medicine Teaching and Mentoring Academy

2022-present Ordinary Member, International Society of Neuroimmunology

2008-present Member, San Francisco Neurological Society

2016-present Member, California Neurology Society; Sacramento, CA

2025-present Member, American Association for the Advancement of Science (AAAS)

**Editorial Boards and Review Committees:**

2025-present Review Committee, National Institute of Allergy & Infectious Diseases of the National Institutes of Health (NIAID/NIH), MS R34 applications for NIAID Clinical Trial Planning Grants

2024-present Reviewer, *BMC Neurology*  
2022-present Review Editor for Multiple Sclerosis and Neuroimmunology;  
*Frontiers in Neurology & Frontiers in Immunology*; loop.frontiersin.org  
2013-2017 Reviewer, *Multiple Sclerosis Journal*  
2008-2013 Ad-hoc Reviewer, *Continuum: Lifelong Learning in Neurology*

### Peer Reviewed Publications:

ORCID id identifier: <http://orcid.org/0000-0002-1721-6081>

[18F] Flurimedrimer, a Novel Nanomedicine Radiotracer, Selectively Targeting Activated Microglia in Human Brain. Moradi, F., **Dunn, J.**, James, M., Malik, N., Park, J., Korn, R., El-Shaafey, N., Lomen-Hoerth, C., Shah, V., Cleland, *J. Soc Nuclear Medicine* 2025. Web of Science 0015457006000040

Major depressive disorder in Multiple Sclerosis associated with differences in disease modifying therapy and demographics. Lee NJ, Hui G, Pike W, Galetta K, Kipp LB, **Dunn JE**, Le S, Folmsbee S. *Front. Neurol* 14 Sep 2025; Volume 16 | doi.org/10.3389/fneuro.2025.1663778

Single-cell Peripheral Immunoprofiling of Lewy Body Disease in a Multi-site Cohort. Thanaphong Phongpreecha, Kavita Mathi, Brenna Cholerton, Eddie J. Fox, Camilo Espinosa, Ling-Jen L. Hwang, Natalia Sigal, Chandresh Gajera, Eloise Berson, Amalia Perna, Feng Xie, Chi-Hung Shu, Debapriya Hazra, Momsen Reincke, Philips Chung, Divya Channappa, **Jeffrey Dunn**, Lucas B. Kipp, Kathleen L. Poston, Kathleen S. Montine, Holden T. Maecker, Nima Aghaeepour, Thomas J. Montine. *Molecular Neurodegeneration* 2024; 19 (1): 59

Clinical Features of Neurotoxicity Following C D-19 CAR-T Cell Therapy in Mantle Cell Lymphoma. Esther Nie, Yi-Jiun Su, John Baird, Neha Agarwal, Sushma Bharadwaj, Wen-Kai Weng, Melody Smith, Saurabh Dahiya, May Han, **Jeffrey Dunn**, Lucas Kipp, David Miklos, Brian Scott, and Matthew Frank. *Blood Advances* ADV-2023-011896R2. 20 Jan 2024 PubMedID 38295285

Predictors of Relapse in ozanimod treated patients with Multiple Sclerosis: *Ad Hoc* Analysis from the Open Label Extension DAYBREAK Study: Coyle, P., **Dunn, J.**, Kappos, L., Moss, B., Cheng, C-Y., Thorpe, A., Morello, JP, Silva, D. and Filippi, M.: SAGE Publications LTD. 2023: 957-958

Epidemiological and Clinical Outcome Determinants of Post-COVID-19 Myelopathy Sumera, J., Sarkar, T., McDonald, J., Sattarnezhad, N., Nie, E., Kipp, L., **Dunn, J.**, Han, M., Joseph, Y., Tomczak, A., Lock, C. SAGE Publications LTD. 2023: 719

SARS-CoV-2 Vaccine Immune Response on Anti-Complement Therapy, Eculizumab. Neda Sattarnezhad, Julia Sumera, Jamie McDonald, Esther Nie, Anna Tomczak, Yamuna Joseph, Sujatha Kalle, Tara Sarkar, Lucas Kipp, Christopher Lock, **Jeffrey E. Dunn**, May Han *Neurology* Apr 2023, 100 (17 S2) 4922; DOI: 10.1212/WNL.0000000000204308

Myelin Oligodendrocyte Glycoprotein Antibody Disease (MOGAD) in conjunction with Allogeneic Bone Marrow Transplantation and Autoimmune Neutropenia: A study of two companion cases and institutional review of the MOGAD clinical phenotype spectrum. Esther Nie, Jamie McDonald, **Jeffrey Dunn**, May Han: *Neurology* Apr 2023, 100 (17 S2)4912 DOI:10.1212/WNL.0000000000204302

Biomarker panel increases accuracy for identification of an MS relapse beyond NfL. Saurabh Gawde, Agnieszka Agasing, Neal Bhatt, Mackenzie Tolliver, Gaurav Kumar, Kaylea Massey, Andrew Nguyen, Yang Mao-Draayer, Wade Dejager, Joel M. Guthridge, Gabriel Pardo, **Jeffrey Dunn**, Robert C. Axtell. *MSRD June 2022*: doi.org/10.1016/j.msard.2022.103922

The B Cell Repertoire in Multiple Sclerosis Reveals Molecular Mimicry between EBV EBNA1 and GialCAM. Tobias V. Lanz, R. Camille Brewer, Peggy P. Ho, Kevin M. Jude, Daniel Fernandez, Ricardo A. Fernandes, Alejandro Gomez, Gabriel Nadj, Ryan D. Schubert, Bianca Teegen, **Jeffrey E. Dunn**, Christopher B. Lock, Lucas B. Kipp, Victoria C. Cotham, Beatrix M. Ueberheide, Blake T. Aftab, Michael R. Wilson, Rachael J.M. Bashford-Rogers, Michael Platten, Raymond A. Sobel, Christopher K. Garcia, Lawrence Steinman, William H. Robinson. 2021-06-09836C. *Nature* 10 Mar 2022

Human KIR+CD8+ T cells target pathogenic T cells in celiac disease and are active in autoimmune diseases and COVID-19. Li, Jing; Zaslavsky, Maxim Elisha; Su, Yapeng; Sikora, Michael; Vincent Van Unen; Christophersen, Asbjørn; Shin-Heng Chiou; Chen, Liang; Li, Jiefu; Ji, Xuhuai; Wilhelmy, Julie; Mcsween, Alana; Palanski, Brad A; Mallajosyula, Vamsee; Dhondalay, Gopal; Bhamidipati, Kartik; Pai, Joy; Kipp, Lucas; **Dunn, •** \_ Human KIR+CD8+ T cells target pathogenic T cells in celiac disease and are active in autoimmune diseases and COVID-19. Li, Jing; Zaslavsky, Maxim Elisha; Su, Yapeng; Sikora, Michael; Vincent Van Unen; Christophersen, Asbjørn; Shin-Heng Chiou; Chen, Liang; Li, Jiefu; Ji, Xuhuai; Wilhelmy, Julie; Mcsween, Alana; Palanski, Brad A; Mallajosyula, Vamsee; Dhondalay, Gopal; Bhamidipati, Kartik; Pai, Joy; Kipp, Lucas; **Dunn, Jeffrey**; Hauser, Stephen; Oksenberg, Jorge; Satpathy, Ansuman; Robinson, William; Steinmetz, Lars; Khosla, Chaitan; Utz, Paul; Sollid, Ludvig M; Heath, James; Fernandez-Becker, Nielsen; Nadeau, Kari; Saligrama, Naresha; Davis, Mark. *Science* 376 (6590); 265. *Science* 376, eabi9591 (2022). DOI.org/10.1126/science.abi9591

A case of MOG antibody disorder with pontine involvement mimicking CLIPPERS and extensive transverse myelitis. Keroles, M., Stocksdales, B., Ng, J., Ahadi, S., and **Dunn, J. J.** Lippincott Williams & Wilkins 2022. Web of Science ID 00089402050090

Consensus Curriculum for Fellowship Training in Multiple Sclerosis and Neuroimmunology. Le H. Hua, Ahmed Obeidat, Lilyana Amezcua, Jeffrey A. Cohen, Kathleen Costello, **Jeffrey Dunn**, Jeffrey Gelfand, Myla Goldman, Sarah Hopkins, Douglas Jeffery, Stephen Krieger, Scott Newsome, Suma Shah, Nancy Sicotte, Vijayshree Yadav, Erin Longbrake. *Neurology Clinical Practice* August 2021; 11; (4): 352-357: doi: 10.1212.CPJ.000000000000104

Defining the Neuroimmunology/Multiple Sclerosis Subspecialty: Surveys of Fellowship Training in the United States. Longbrake, E., Obeidat, A., **Dunn, J.**, Sicotte, N., Hua, L. Lippincott Williams & Wilkins 2020. Web of Science # 000536058001053

Advocacy, Dissemination and Implementation Strategies for an International Standardized MRI Protocol for Diagnosis and Follow-Up of patients with Multiple Sclerosis. Saslow, L., Li, D., Halper, J., Banwell, B., Barkhof, F., Barlow, L., Costello, K., Damiri, B., **Dunn, J.**, Giri, S., Maes, M., Morrow, S., Newsome, S., Oh, J., Friedemann, P., Quarterman, P., Reich, D., Shewchuk, J., Shinohara, R., Van Hecke, W., Van de Ven, K., Wallin, M., Wolinsky, J., Traboulsee, T. *Int J MS Care*. 2020; 22:226-232.

Repopulation of T, B and NK cells following alemtuzumab treatment in relapsing-remitting Multiple Sclerosis. Gilmore, W., Lund, B., Li, P., Levy, A., Kelland, E., Akbari, O., Groshen, S., Yong, S., Pelletier, D., Weiner, L., Javed, A., **Dunn, J.**, Traboulsee, T. *Journal of Neuroinflammation* 2020; 17 (1): 189

Current State and Frontiers in the Treatment of Multiple Sclerosis: Report of an Expert Meeting. Hartung, H-P, Berger, J., Berkovich, R., **Dunn, J.**, Gass, A., Haas, J., Katri, B., Kleinschnitz C., Tackenberg, B., Weinstock-Guttman, B., Wiedndl, H., Zamvil, S., Zimssen, T., Gold, R. *Therapeutic Advances in Neurologic Disorders (SAGE)* 2019

The North American Registry for Care and Research in Multiple Sclerosis. Rammohan, KW, Li, D., Halper, J., Murphy, S., Patton, L., Berger, J., Carlson, A., China, A., Cohan, S., Cross, A., **Dunn, J.**, Fox, E., Gupta, A., Kamin, S., Mao-Draayer, Y., Mayer, L., Repovic, P., Ruiz, J., Rus, H., et al. *Sage Publications LTD.* 2019: 79-80

Autoimmune Hepatitis During Treatment of Multiple Sclerosis with Alemtuzumab. A Carlson, N Bozinov, L Kipp, **J Dunn**, C Lock. *Neurology* April 9, 2018 vol. 90 no 15 supplement P5.350.

Infectious Complications of Multiple Sclerosis Therapies: Implications for screening, prophylaxis, and management. Epstein, D.J., **Dunn, J.**, Deresinski, S. *Open Forum Infectious Diseases* S.2018; 5 (8) ofy17

Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis. Hauser S., et. al., **OPERA II Clinical Investigators.** *New England Journal of Medicine* 19 Jan 2017; 376; 3: 221-234 (*site PI for OPERA Trial*)

Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients. Giovannoni G., et al., **CARE-MS II Investigators.** *Neurology* 2016; 87: 1985-1992 (*Site PI*)

Interferon beta treatment requires B-cells for efficacy in neuro-autoimmunity. Schubert R., Hu Y., Kumar G., Szeto S., Abraham P., Winder, J., Guthridge JM, Pardo G., **Dunn J.**, Steinman L., Axtell R.C. *Journal of Immunology*, 2015; 194 (5): 2110-2116

Disease Modifying Therapies for non-relapsing Multiple Sclerosis: Absence of evidence does not constitute evidence of absence. **Dunn, J.** *Neurol Clin Pract.* December 2013; 3 (6): 515-518

Mobility Concerns in Multiple Sclerosis- Studies and Surveys on US patient populations of relevance to nurses. Lee, J., **Dunn J.** *US Neurology*; 2013; 9(1): 17-23

Lublin, F. et al. and **CombiRx Investigators.** Randomized study combining interferon and glatiramer acetate in Multiple Sclerosis. *Ann Neurol* 2013 Mar; 73 (3): 327-340 (*site PI*)

The CombiRx Trial of Combined Therapy with interferon and glatiramer acetate in relapsing remitting Multiple Sclerosis: design and baseline characteristics. Lindsey, J. et al. and **CombiRx Investigators.** *Mult Scler Relat Disord.* 2012 April 1; 1 (2): 81-86 (*site PI*)

Alemtuzumab for patients with relapsing Multiple Sclerosis after disease-modifying therapy: a randomized controlled Phase 3 trial. Coles AJ, et al. **CARE MS II Investigators.** *Lancet* 2012; 380: 1829-1839 (*site PI*)

Protective effect of elastase inhibitor in a neuromyelitis optica-like disease driven by a peptide of myelin oligodendroglial glycoprotein. Herges K, deJong BA, Kolkowitz I, Dunn C, Mandelbaum G, Ro RM, Maini A, Han, MH, Killestein J. Polman C, Goodyear A, **Dunn J.**, Steinman L, Axtell RC; *Multiple Sclerosis* 2012; 18 (4): 398-408

Dalfampridine: A Brief Review of Its Mechanism of Action and Efficacy as a Treatment to Improve Walking in Patients With Multiple Sclerosis; **Dunn J.**, Blight D. *Curr Med Res Opin.* 2011 Jul;27(7):1415-23

The impact of mobility impairment on the burden of caregiving in individuals with Multiple Sclerosis. **Dunn J.** *Expert Rev Pharmacoecon Outcomes Res:* 2010 Aug; 10 (4) 433-440

CMV Optic Neuritis with extensive tracking along the visual pathway: Pershing S, **Dunn J.**, Khan A, Liao YJ; *J Neuroophthalmology* 2009; 29 (3):223-226

Glatiramer acetate after induction therapy with mitoxantrone in relapsing Multiple Sclerosis: Vollmer, T., Panitch, H., Bar-Or, A., **Dunn, J.**, Freedman, M., Gazda, S.K., Campagnolo, D., Deutsch, F. and Arnold, D.: *Multiple Sclerosis* 2008; 14: 663-670

Glatiramer acetate after mitoxantrone induction improves MRI markers of lesion volume and permanent tissue injury in MS; Arnold, D.L., Campagnolo, D., Panitch, H., Bar-Or, A., **Dunn J.**, Freedman, M.S., Gazda, S.K., Vollmer, T: *J Neurol* 2008; 255: 1473-1478

Tovaxin for early relapsing Multiple Sclerosis Phase 2b placebo controlled trial of autologous T-cell vaccination in patients with Clinically Isolated Syndrome or relapsing remitting MS: Fox, EJ and The **TERMS Study Investigators:** *Multiple Sclerosis* 2008;14: S5-S27 (site PI)

Ginkgo Biloba in the Treatment of Alzheimer's Disease. **Dunn, J.**, Maidan, R. and Pallis, J.; *Alternative Medicine; December 1998: Volume I, Issue 15; 1-2*

Atherosclerotic Aortic Disease as a source of embolic infarct; Bursell, John P., Odderson, I. and **Dunn, J.;** *Journal of Neurovascular Disease* 1996; 1; 2: 35-38

Intracerebral Bacillary Angiomatosis in a patient infected with HIV; Spach, D., Panther, L., Thorning, D., **Dunn, J.** Plorde, J.L., Miller, R.; *Annals of Internal Medicine;* 1992: 116; 740-743

#### **Abstracts, posters and presentations:**

**J. Dunn,** K. Galetta, G. Timmons, A. Tomczak, J. McDonald, E. Martinez, B. Sahaf, E. Meyer, T. V. Lanz, R. Lowsky. Chimeric Antigen Receptor T cell (CAR-T) immunotherapy for progressive phenotypes of Multiple Sclerosis: ongoing results from a prospective Phase 1, open-label, single center study of an autologous fully human anti-CD19 CAR-T. *In: Americas Committee for Treatment & Research in MS (ACTRIMS):* Abstract 2026-A-265. 06 Feb 2026; San Diego, CA, USA: submitted

W Brownlee, X Montalban, V Campbell, N Cunniffe, P Ferguson, F Pérez-Miralles, B Sharrack, N Dhungana, D Germano, J Willmer, **J Dunn.** Evaluating the Safety, Tolerability and Preliminary Efficacy of Obecabtagene autoleucel in Patients with Refractory Progressive Forms of Multiple Sclerosis: The BOBCAT Trial. *In: Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS);* 06 Feb 2026; San Diego, CA, USA: submitted

G. Timmons, A. Tomczak, E. Martinez, M. Manojkar, T. Lanz, K. Galetta, R. Lowsky, **J. Dunn** Cytokine profiling in a Phase 1 study of autologous fully-humanized anti-CD19 chimeric antigen receptor T cell (CAR-T) immunotherapy for progressive phenotypes of Multiple Sclerosis. *In: Americas*

*Committee for Treatment & Research in MS (ACTRIMS)*: Abstract 2026-A-265. 06 Feb 2026; San Diego, CA, USA: poster presentation

Held F, Lanz T, **Dunn J**. Targeting EBNA1 epitopes to block cross-reactive immunity in Multiple Sclerosis (TARGET-MS). In: *Translational Research and Applied Medicine Scholars Conference*; 01 Oct 2025; Stanford University, Stanford, CA: oral presentation

**Dunn J**, Galetta K, Lanz T, Tomczak A, Timmons G, Martinez E, Manohar M, Sahaf B, McDonald J, Meyer E, Lowsky R. Chimeric antigen receptor T Cell (CAR-T) immunotherapy for progressive phenotypes of Multiple Sclerosis: Early results from a Phase 1 open-label single center study of an autologous fully humanized anti-CD19 CAR. In: *European Committee for Treatment & Research in Multiple Sclerosis (ECTRIMS)*; 24 Sep 2025; Barcelona, Spain: Platform Presentation.

Sattarnezhad N, Held F, Babaei M, Gawde S, Ho P, Barret A, Wijeratne T, Comanescu A, Parsafar S, Bartels F, McDonald J, Kipp L, Van Haren K, Chachian Y, Lock C, Han M, Baker M, **Dunn J**, Steinman L, Lanz T, Robinson W. Distinct Reactivity Patterns to EBV Nuclear Proteins and CNS Antigens Distinguish CNS Demyelinating Disorders from Systemic Autoimmunity. In: *European Committee for Treatment & Research in Multiple Sclerosis (ECTRIMS)*: 26 Sep 2025; Barcelona, Spain: Poster presentation # P241.

Sumera J, Joseph Y, Tomczak A, Martinez E, JCuevas J, Ton-Nu C, Wu D, Loeffler J, McDonald J, Galetta K, Kipp L, Melamed E, **Dunn J**, Moss H, Han M, Lock C. Plasma Analysis of Immune-Mediated Myelopathies Reveals Upregulation of Autoimmune Signatures in Idiopathic Transverse Myelitis Compared to Other Central Nervous System Inflammatory Demyelinating Disorders. In: *Pan-Asian Committee for Treatment & Research in Multiple Sclerosis PACTRIMS*; 14 Nov 2025; Osaka, Japan: poster presentation.

*Chimeric Antigen Receptor T Cell Immunotherapy for Progressive Phenotypes of Multiple Sclerosis: early results from a Phase 1, Open Label Single Center Study of an Autologous Fully Humanized Anti-CD-19 CAR-T*. **Jeffrey Dunn**, Anna Tomczak, Kristin Galetta, Garrett Timmons, Emma Martinez, Tobias Lanz, Monali Manohar, Bitu Sahaf, Everett Meyer, Robert Lowsky. European Committee for the Treatment and Research of Multiple Sclerosis, 41st ECTRIMS Congress. Abstract # 2978; abstract category 4 Therapy- Immunomodulation. Barcelona, Spain: 23 Sept 2025

*Distinct Reactivity Patterns to EBV Nuclear Proteins and CNS Antigens Distinguish CNS Demyelinating Disorders from Systemic Autoimmunity*. Neda Sattarnezhad, Friederike Held, Mahsa Babaei, Saurabh Gawde, Peggy P. Ho, Alison K. Barret, Tilini Wijeratne, Alexandros I. Comanescu, Shima Parsafar1, Frederik Bartels, Jamie C. McDonald, Lucas Kipp, Keith Van Haren, Yashaar Chaichian, Christopher B. Lock, May H. Han, Matthew C. Baker, **Jeffrey Dunn**, Lawrence Steinman, Tobias V. Lanz, William H. Robinson. 41<sup>st</sup> ECTRIMS Congress. Barcelona, Spain: 24 September 2025

*18-F-Flurimedrimer, a Novel Nanomedicine Radiotracer, Selectively Targeting Activated Microglia in Human Brain*. Farshad Moradi, **Jeffrey Dunn**, Michelle James, Ronald Korn, Cathy Lomen-Hoerth, Vinil Shah, Jeffrey Cleland. Society of Nuclear Medicine and Molecular Imaging. SNMMI Annual Meeting. New Orleans, LA, USA: 21-24 June 2025

*Autoimmune Encephalitis in Patients on Immune Checkpoint Inhibitor Therapy: a Case Series*. Kirschenbaum, D., **Dunn, J.**, McDonald, J., Galetta, K. Stanford University 12<sup>th</sup> Annual Neuroscience Forum. Palo Alto, California USA: 16 May 2025

*A Phase I, Open-label, Single Center Study of KYV-101, an Autologous Fully-human Anti-CD-19+ Chimeric Antigen Receptor T Cell (CD19 CART) in Subjects with Progressive Forms of Multiple Sclerosis.* **Jeffrey Dunn MD**, Anna Tomczak MS, Kristin Galetta MD, Garrett Timmons MD, Monali Manohar PhD, Everett Meyer MD, Robert Lowsky MD. American Academy of Neurology, invited Oral Platform Abstract # 5371. San Diego, CA USA: 06 April 2025

*Comparing brain MRI-derived whole brain and grey matter volumes with patient reported outcomes in a cohort of people living with MS.* Garrett Timmons MD, Anna Tomczak MA, **Jeffrey Dunn MD**. American Academy of Neurology Annual Meeting. Poster Session. San Diego, CA USA: 07 April 2025

*Autoimmune encephalitis in patients on immune checkpoint inhibitor therapy: a case series.* Kirschenbaum, D; **Dunn, J**; McDonald, J; Galetta, K. 12<sup>th</sup> Annual Stanford Neuroscience Forum. Stanford Center for Academic Medicine; Stanford, CA USA: 16 May 2025

*A Phase I Open Label, Single Center Study of KYV-101, an Autologous Fully Human Anti-CD-19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects with Progressive Forms of Multiple Sclerosis.* **Jeffrey Dunn MD**, Anna Tomczak MS, Kristin Galetta MD, Garrett Timmons MD, Monali Manohar PhD, Everett Meyer MD, Robert Lowsky MD. Poster session P108 Abstract # 530 Americas Committee for Treatment & Research of Multiple Sclerosis ACTRIMS, West Palm Beach, FL, USA: 28 Feb 2025

*Science Breakthroughs of The Year: Unleashing Immune Cells on Autoimmune Disease.* Monalisa Ghosh MD, **Jeffrey Dunn MD**, Aimee Payne MD PhD. American Association for the Advancement of Science AAAS Annual Meeting; Session # 35801. Boston, MA USA: 15 Feb 2025

*Multiple Sclerosis and Major Depressive Comorbidity: Implications in Social Determinants of Health and Clinical Outcomes.* Nathanael Lee, Kristin Galetta, Lucas Kipp, **Jeffrey Dunn**, Scheherazade Le, S. Sai Folmsbee. ACTRIMS Annual Forum. West Palm Beach, Florida, USA: 28 Feb 2025

*Reactivity to Epstein Barr Virus Differentiates Multiple Sclerosis from Systemic Autoimmunity.* Sattarnezhad, N., Babaei, M., Sawde, S., Ho, P., Barret, A., Wijerante, T., Comanescu, A., Parsafar, S., McDonald, J., Kipp, L., Van Haren, K., Lock, C., Han, M., Baker, M., **Dunn, J.**, Steinman, L., Lanz, T., Robinson, W. American Academy of Neurology. San Diego, CA USA: April 2025

*Harnessing the Power of CAR-T therapies in Neurological Autoimmune Diseases.* Aiden Haghikia MD, **Jeffrey Dunn MD**, Dimitros Mougiakakos MD. *Medscape international CME*; [https://www.medscape.org/viewarticle/1001590\\_2](https://www.medscape.org/viewarticle/1001590_2): November 2024

*A Phase 2, Open-Label, Randomized, Multicenter Study of KYV-101, an Autologous Fully Human Anti-CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy, in Treatment Refractory Primary and Secondary Progressive Multiple Sclerosis.* **Jeffrey Dunn**, Manuel A. Friese, Bruce A. C. Cree, Marshelle Warren Smith, Kunbin Qu, Dominic Borie, James Chung, Ralf Gold: P1594. ECTRIMS 40<sup>th</sup> Congress; Copenhagen, Denmark: 18-20 September 2024

*Predictors of Relapse in ozanimod treated patients with Multiple Sclerosis: Analysis from the Open Label Extension DAYBREAK Study:* Coyle, P., **Dunn, Jeffrey**, Kappos, L., Sheffield, JK, Riolo, J.V., Cheng, C-y, Thorpe, A. and Filippi, M.: # P1639; ECTRIMS 2024: Copenhagen, Denmark:18-20 Sep 2024

*Design of KYSA-7, A Phase 2, Open-Label, Randomized, Multicenter Study of KYV-101, an Autologous Fully Human Anti-CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy, in Refractory Primary and Secondary Progressive Multiple Sclerosis.* Jeffrey Dunn, Manuel A. Friese, Bruce Cree, Marshelle Warren Smith, Kunbin Qu, Dominic Borie, James Chung, Ralf Gold. DGN 2024 (Deutschen Gesellschaft für Neurologie; [kongress@dgn.org](mailto:kongress@dgn.org)): Abstract # 341, Poster P175: Berlin, Germany: 07 Nov 2024

*Paired serum and CSF immunoprofiling guides treatment of refractory autoimmunity.* Danwei Wu, Tara Sarkar, Anna Tomczak, Esther Nie, Kristin Galetta, Jamie McDonald, Julia Sumera, Lucas Kipp, Christopher Lock, Jeffrey Dunn, May Han.ECTRIMS 40<sup>th</sup> Congress; Copenhagen, Denmark: 18-20 September 2024

*Hi-dimensional, targeted immunogenetic profiles of “idiopathic” myelitis with correlative risk and protective factors.* Tara Tripathi Sarkar, Julia Sumera, Anna Tomczak, Safiyyah Bachar, Crystal Ton-Nu, Yamuna Joseph, Kazutoyo Osoegawa, Marcelo A Fernandez Vina, Danwei Wu, Esther Nie, Neda Sattarnezhad, Jamie McDonald, Kristin Galetta, Lucas Kipp, Keith Van Haren, Jeffrey Dunn, May Han, Christopher Lock:ECTRIMS 40<sup>th</sup> Congress; Copenhagen, Denmark: 18-20 September 2024

*Impact of social determinants of health in diagnosing Creutzfeldt-Jakob Disease.* Nathanael J. Lee, Jeffrey Dunn, Kristin Galetta: AAN Autoimmune Neurology Summer Conference; 01 May 2024: Atlanta, Georgia

*The Project BIG Biorepository.* Anna Tomczak, MS, Yamuna Joseph, MD, Julia Sumera, BA, Tara Sarkar, BA, Safiyyah Bachar, BA, Crystal Ton-Nu, BA, Esther Nie, MD, Danwei Wu, MD, Jamie McDonald, MD MS, Lucas Kipp, MD, Christopher Lock, MD, May Han, MD, Jeffrey Dunn, MD: American Academy of Neurology Annual Meeting; Poster session P3; Denver, Colorado: 14 April 2024

*Bridging the Gap Between Science and Practice: Starting with the Project BIG Biorepository.*Anna Tomczak, MS, Yamuna Joseph, MD, Julia Sumera, BA, Tara Sarkar, BA, Safiyyah Bachar, BA, Crystal Ton-Nu, BA, Esther Nie, MD, Danwei Wu, MD, Jamie McDonald, MD MS, Lucas Kipp, MD, Christopher Lock, MD, May Han, MD, Jeffrey Dunn, MD: ACTRIMS (Americas Committee for the Treatment and Research of Multiple Sclerosis); Abstract # 513, Poster 378, Session 2: West Palm Beach, Florida: 29 February 2024

*Analysis of the Stanford University myelitis cohort from 1986-2023: Idiopathic myelitis accounts for 6.6% of cases.* Julia Sumera, BA, Anna Tomczak, MS, Tara Tripathi Sarkar, BS, Yamuna Joseph, MD, Crystal Ton-Nu, BS, Safiyyah Bachar, MS, Jamie McDonald, MD MS, Danwei Wu, MD, Esther Nie, MD, Lucas Kipp, MD, Jeffrey Dunn, MD, May Han, MD, Christopher Lock, MD, PhD: American Academy of Neurology Annual Meeting; Denver, Colorado: April 2024

*Clinical and Neuroradiological Features of Immune Effector Cell-associated Neurotoxicity Syndrome (ICANS) following CD19 CAR T-cell therapy in Mantle Cell Lymphoma.* Nie EH, Su Yi-Jiun, Baird JH, Agarwal N, Bharadwaj S, Wen W, Smith M, Dahiya S, Dunn JE, Han, MH, Kipp LB, Miklos DB, Scott BJ, Frank MJ: American Academy of Neurology Annual Meeting; Denver, CO: April 2024

*Predictors of Relapse in ozanimod treated patients with Multiple Sclerosis: Analysis from the Open Label Extension DAYBREAK Study:* Coyle, P., Dunn, J., Kappos, L., Moss, B., Cheng, C-Y., Thorpe, A., Morello, JP, Silva, D. and Filippi, M.: MS Milan 2023.ECTRIMS-ACTRIMS ePoster # P1503; Milan, Italy: 11-13 October 2023

*Epidemiologic and Clinical Determinants of post-COVID-19 Transverse Myelitis.* Julia Sumera, BA, Anna Tomczak, MS Tara Tripathi Sarkar, BS, Yamuna Joseph, MD, Crystal Ton-Nu, BS, Safiyyah Bachar, MS, Jamie McDonald, MD MS, Esther Nie, MD, Danwei Wu, MD, Lucas Kipp, MD, **Jeffrey Dunn, MD**, May Han, MD, Christopher Lock, MD, PhD ECTRIMS-ACRIMS ePoster ; Milan, Italy: 11-13 October 2023

*Myelin Oligodendrocyte Glycoprotein antibody disease (MOGAD) in conjunction with Allogeneic Bone Marrow Transplantation and Autoimmune Neutropenia: A study of two companion cases and institutional review of the MOGAD clinical phenotype spectrum.* Nie EH, McDonald J, **Dunn JE**, Han MH.: American Academy of Neurology Annual Meeting; Boston, MA: 27 April 2023: P13

*SARS-CoV-2 Vaccine Immune Response on Anti-Complement Therapy with Eculizumab.* Sattarnezhad, N., Sumera, J., McDonald, J., Nie, E., Tomczak, A., Joseph, Y., Kalle, S., Sarkar, T., Kipp, L., Lock, C., **Dunn, J.** and Han, M.: ACRIMS Forum 2023 abstract # 802, P117; San Diego, CA: 24 Feb 2023

*Pattern of cognitive dysfunction associated with Neuromyelitis Optica and Myelin Oligodendrocyte Antibody-associated disease.* Wilson, E., McDonald, J., Sattarnezhad, N., Nie, E., Sumera, J., Joseph, Y., Kalle, S., Sarkar, T., Kipp, L., Lock, C., **Dunn, J.**, Deutsch, G., Vlahovic, L., Han, M. ACRIMS Forum 2023; San Diego, CA: 23 Feb 2023

*Retrospective Investigation of Vitamin D Deficiency as Independent Risk Factor for Transverse Myelitis.* Julia Sumera, BA, Anna Tomczak, MS, Sujatha Kalle, MD, Jamie McDonald, MD MS, Neda Sattarnezhad, MD, Evan Madill, MD, Lucas Kipp, MD, Christopher Lock, MD, **Jeffrey Dunn, MD**, May Han, MD: ECTRIMS 2022; Amsterdam, The Netherlands

*A Retrospective Investigation of MOG-IgG Titers in Relapse and Disability Prediction in Adult and Pediatric Myelin Oligodendrocyte Glycoprotein Antibody Disease Patients.* Jamie McDonald MD MS, Jonathan D. Santoro MD, Neda Sattarnezhad MD, Anna Tomczak MS, Julia Sumera BA, Keith Van Haren MD, Nicole Corwin MS, Lucas Kipp MD, Christopher Lock MD PhD, **Jeffrey Dunn MD**, Jessica Hinman MS, Lorene Nelson PhD, May Han MD; ECTRIMS 2022; Amsterdam, The Netherlands

*Association of Hormonal Dysregulation with Clinical- and Patient-Reported Outcomes in Pediatric Multiple Sclerosis.* Neda Sattarnezhad, MD, Mellad Khoshnood, MD, Natalie Boyd, BS, Nusrat Ahsan, MD, **Jeffrey Dunn, MD**, Jonathan D. SanSARS-CoV-2 Vaccine Immune Response no Anti-Complement Thetoro, MD: ECTRIMS 2022; Amsterdam, The Netherlands

Invited platform and poster presentation: *Adaptive B cell and T cell responses to CoV-2 vaccination in patients with Multiple Sclerosis on disease modifying immunotherapy.* Tomczak, A., Sumera, J., Joseph, Y., Wu, D., McDonald, J., Sattarnezhad, N., Kipp, L., Lock, C., Hay, M., and **Dunn, J.** : ACRIMS. 22 Feb 2022. West Palm Beach, Florida

*New onset headache in neurosarcoidosis: An early sign of leptomeningeal involvement.* Wu, D., Tomczak, A., Sattarnezhad, N., McDonald, J., Sumera, J., Kipp, L., Lock, C., **Dunn, J.**, Han, M. : ACRIMS: 23 Feb 2022. West Palm Beach, Florida

*ACTonMS Virtual Think Tank White Paper: 3 Complementary Transitions in Patient Care Inspired by Health Care Innovations in Response to the Pandemic.* Cleveland Clinic Foundation **National Expert panel.** 2021

*MS Treatment Guidelines during the Coronavirus pandemic.* Miller, A., **Dunn, J.**, Costello, K. and NMAC, National Multiple Sclerosis Society; 2020

*The North American Registry for Care and Research in Multiple Sclerosis.* Kottil Rammohan, David Li, June Halper, Sara McCurdy Murphy, Lisa Patton, Joseph Berger, Aaron Carlson, Angel Chinae, Stanley Cohan, Anne Cross, **Jeffrey Dunn**, Edward Fox, Ajay Gupta, Stephen Kamin, Yang Mao-Draayer, Lori Mayer, Pavle Repovic, Jennifer Ruiz, Horea Rus, Rohini Samudralwar, Adnan Subei, Florian Thomas: ACTRIMS; 01 March 2019: Dallas, Texas

*Systems approaches to discovering T cell antigen (s) in neurological diseases* [poster and oral presentation]. N Saligrama, F Zhao, MJ Sikora, WS Serratelli, RA Fernandes, DM Louis, W Yao, X Ji, J Idoyaga, VB Mahajan, LM Steinmetz, Y Chien, SL Hauser, JR Oksenberg, LB Kipp, **J Dunn**, CK Garcia, MM Davis. Neuroimmune Communication in Health and Disease, Ventura, CA. January 13, 2019 -January 18, 2019

*Autoimmune Hepatitis During Treatment of Multiple Sclerosis with Alemtuzumab.* Carlson A., Kipp L., Charville G., Sherman C., **Dunn, J.**, Lock C. American Academy of Neurology Annual Meeting; abstract # 1069; position 350. Los Angeles, CA: 26 April 2018

*Positive GAD-65 antibodies in patients with autonomic dysfunction.* L Vlahovic, L Kipp, **J Dunn**, L Nguyen, S Jaradeh. 28th International Symposium on the Autonomic Nervous System; 2017 Nov 1-4; Clearwater Beach, Florida, USA

*Leukocyte repopulation following alemtuzumab treatment in relapsing-remitting Multiple Sclerosis contains multiple regulatory immune cell types.* Lund B., Traboulsee A., Javed A., **Dunn J.**, Weiner L., Li P., Kelland E., Levy A., Gilmore W. P979. Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS-ACTRIMS); Paris, France: 25-28 October 2017

*Positive GAD-65 antibodies in patients with autonomic dysfunction.* Vlahovic L., Kipp, L., **Dunn, J.**, Nguyen L., Jaradeh, S. 2017

*Assessment and Management Strategies for Relapsing Multiple Sclerosis Patients with Breakthrough Disease and Suboptimal Treatment Response.* **Dunn J.**; Clin-Topics; January 2017; FCH-US-2262; pages 1-6

*Alemtuzumab Significantly Improves Disability in Patients with Active Relapsing-Remitting Multiple Sclerosis and an Inadequate Response to Prior Therapy as Assessed Using a Novel, Composite Measure of Confirmed Disability Improvement: Results from CARE-MS II.* Singer B., **Dunn J.**, Izquierdo G., Thangavelu K., Mittal A., Pozzilli C., on behalf of MS-CARE II Investigators; 32nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS); London, England, UK: 14-17 Sept 2018

*T cell-driven dimethyl fumarate induced lymphopenia in patients with Multiple Sclerosis.* Lee J-M, Lock, C., Ho, P and **Dunn J.**; Consortium of Multiple Sclerosis Centers annual meeting; National Harbor, Maryland: 2 June 2016

*T cell-driven dimethyl fumarate induced lymphopenia in patients with MS.* Lee, J-M, and **Dunn, J.E.**; PACTRIMS; 20 Nov 2015: Seoul, South Korea

*Characteristics of leukocyte recovery following treatment with humanized anti-CD52 (alemtuzumab/Lemtrada) in multiple sclerosis.* W. Gilmore, B.T. Lund, A. Traboulsee, A. Javed, **J.E. Dunn**, L.P. Weiner, P. Li, E.E. Kelland, A.M. Levy; ECTRIMS; 9 October 2015: Barcelona, Spain

*The Utility of Magnetic Resonance Imaging in Multiple Sclerosis.* **Dunn, J.**; PACTRIMS Pan-Asian Committee for Treatment and Research in Multiple Sclerosis; 7 Nov 2014: Taipei, Taiwan

*Discovery of a novel peripheral blood B cell signature of interferon beta therapy in MS.* Schubert R.D., Abraham P., Goodyear A., Steinman L., Senior authors: **Dunn J.**, Axtell R.; Stanford University School of Medicine Neuroscience Forum; Stanford, CA: 7 June 2013

*Analysis of B Cell Subsets in Multiple Sclerosis Patients on Immunomodulatory Therapy Reveals Modulation of CD19+CD24hiCD38hi Cells With Implications for the Diagnosis and Monitoring of MS.* Schubert R., Goodyear A., Abraham P., Dunn C., Steinman L.; Senior authors: **Dunn J.** and Axtell R.; American Academy of Neurology Annual meeting abstract # P03.224; San Diego, CA: 19 March 2013

*MRI Characteristics of CNS Demyelinating Disease in those of Indian Ethnicity.* Hua L., Lee J. and **Dunn J.**; Stanford University School of Medicine Neuroscience Forum; Stanford, CA; 13 May 2011

*Clinical Trials in Multiple Sclerosis, developments and challenges: CHOICE Study*  
**Investigators:** ECTRIMS Annual Congress; Prague, Czech Republic: September 2007

*The Modified Rankin Score as a measure of self-report in MS using baseline assessments.* Colfield S. and the **CombiRx Investigator Group**; ECTRIMS Annual Congress; Prague, Czechoslovakia: September 2007

*Daclizumab in patients with active relapsing Multiple Sclerosis on concurrent interferon beta therapy Week 24 data Phase II.* Montalban X, Kaufman M, Wynn D et the **CHOICE Study**  
**Investigators:** Poster S18; ECTRIMS Annual Congress; Prague, Czechoslovakia: October 2007

*Analyzing relapse assessment in CombiRx;* Cutter et al, **CombiRx Investigator Group**;  
ECTRIMS Annual Congress. Prague, Czechoslovakia: October 2007

*Mitoxantrone as induction followed by Glatiramer Acetate compared to Glatiramer Acetate monotherapy in relapsing Multiple Sclerosis.* Vollmer, T., Panitch, H., Bar-Or, A., **Dunn, J.**, Freedman, M., Gazda, S.K., Campognolo, D. and Arnold, D.; ECTRIMS Annual Congress. Madrid, Spain: September 2006

*Safety and tolerability of Glatiramer Acetate in pediatric patients with relapsing remitting Multiple Sclerosis.* Krupp, L., Banwell, B., Picone, M., **Dunn, J.**, Weinstock-Guttman, B., and Pardo, L.; ECTRIMS Annual Forum. Thessaloniki, Greece: September 2005

*Comprehensive outpatient management of patients with Multiple Sclerosis;* Odderson, I.R., and **Dunn, J.**; *RIMS MS Symposium; May 2001*; 7th Annual RIMS Conference: Copenhagen, Denmark; May 2001

*Novantrone in the treatment of Multiple Sclerosis.* **Dunn, J.**, Kita, M. Lucas, S., Bowen, J. and the Pacific Northwest Alliance of MS Centers; *Alliance News; Fall 2001; 1-3*

*Greater Washington Chapter Clinical Advisory Committee Statement on Procarin.* Bowen, J., **Dunn, J.**, Kraft, G.H., Ratley, G., Shilling, J., Smith, C. and Thompson, L.; *Health Care Connection: Fall 1999: 1, Issue 1; 1-2*

*Stroke: Acute Treatment and Prevention;* 17th Annual University of Washington Review Course in Physical Medicine and Rehabilitation; Odderson, I., **Dunn, J.** et al; March 1996

**Invited faculty, platform, and international oral presentations: (< 7 years):**

Invited Faculty, *Cellular Therapy for Multiple Sclerosis.* Cellular Immune Tolerance Symposium. LKSC Center; Stanford University. Stanford, CA USA: 01 May 2025

Invited Oral Platform Presentation, *A Phase 1, Open-label, Single Center Study of KYV-101, an Autologous Fully Human Anti-CD-19+ Chimeric Antigen Receptor T Cell (CD19 CAR-T) Therapy, in Subjects with Non-Relapsing and Progressive Forms of Multiple Sclerosis.* American Academy of Neurology Annual Meeting; Session S3 Multiple Sclerosis Clinical Trials. Abstract # 5371. San Diego, CA USA: 06 April 2025

Osler Residency Annual Visiting Endowed Professorship in Bedside Medicine and Grand Rounds, *The Excellence in Bedside Medicine Endowed Lectureship 2025.* **Jeffrey Dunn MD.** Johns Hopkins University Department of Medicine, Baltimore, MD USA: 20-21 March 2025

*Science Breakthroughs of The Year: Unleashing Immune Cells on Autoimmune Disease.* Monalisa Ghosh MD, **Jeffrey Dunn MD**, Aimee Payne MD PhD. American Association for the Advancement of Science AAAS Annual Meeting; Session # 35801. Boston, MA USA: AAAS.confex.com/aaas/2025/meetingapp.cgi/session/35801: 15 Feb 2025

Invited Faculty and Module Chair, Neuroimmunology: *CNS Demyelinating Syndromes and the Expanding World of Neuroimmunology.* 13<sup>th</sup> Annual Breakthroughs in Neurologic Therapies CMS Conference. Stanford University Department of Neurology Virtual Symposium. 15 Nov 2024

Invited Faculty, *Harnessing the Power of CAR-T Therapies in Neurological Autoimmune Diseases.* **Jeffrey Dunn, MD** (Stanford), Aiden Haghikia MD (Germany), Dimitrios Mouggiakakos (Germany); Medscape Spotlight: <https://www.medscape.org/viewarticle/1001590>: November 2024

Invited faculty lecture, *Extending CAR-T Immunotherapy to Neuroimmune Diseases,* Neuro-Immuno-Oncology monthly Education Conference, Stanford NIO Medicine: 07 Sep 2024

Invited Roundtable Faculty, *Harnessing the Power of CAR-T Cell Therapies in Neurological Autoimmune Diseases.* Jeffrey Dunn, MD (Stanford), Aiden Haghikia MD (Germany), Dimitrios Mouggiakakos (Germany); Medscape Spotlight ([www.medscape.org](http://www.medscape.org)): 01 September 2024

Invited delegate, *Alexandria Summit: Immunology 2024: Driving Innovation to Advance Human Health;* La Jolla, California: 09 July 2024

Invited Faculty, *CD-19-targeting Chimeric Antigen Receptor T Cell Therapy in Multiple Sclerosis;* Stanford Blood & Marrow Transplantation and Cellular Therapy National Symposium; platform and recorded lecture; Stanford University: 05 April 2024

Invited Faculty, *B In the Know: The basis for pro-active immunotherapy in relapsing MS.*

Henry Ford Neurology Residency Training lecture; Detroit, MI (virtual): 16 Jun 2023

Invited Faculty, *Cell Therapy for Neuroimmune Disease*, Cellular Immune Tolerance Symposium; Li Ka Shing Center, Stanford University School of Medicine; Stanford, CA: 04 May 2023

Invited Grand Rounds Presenter, *Epstein Barr Virus and Multiple Sclerosis: Evidence and Opportunity*. University of South Florida, Morsani College of Medicine; Tampa, Florida: 07 April 2023

Faculty, *Advanced Techniques of the Neurological Exam*  
Stanford 25 Bedside Symposium; Stanford University: 01-02 Oct 2022

Faculty, *EBV and Multiple Sclerosis*,  
California Neurological Society, Annual Meeting; San Diego, CA: 23 Sep 2022

Keynote faculty, *Introduction to Project BIG*,  
Project BIG / Sarafan ChEM-H Kickoff Event; Stanford CheM-H complex: 27 July 2022

Invited faculty, *A Review of Epstein-Barr Virus and its role in Multiple Sclerosis*,  
Nashville, TN: 29-30 April 2022

Faculty & Section Moderator, *The brain, immune and gut research initiative*,  
Stanford Autoimmune & Allergy Supergroup; Wu Tsai Neurosciences: 22-23 April 2022

Invited Faculty, *Evolving Paradigms: The Cause of Multiple Sclerosis*,  
Texas Neurological Society Annual Conference; Austin, TX: 05 Feb 2022

Chairman, *International Panel on the Pathophysiology of Neuromyelitis Optica Spectrum Disorders: Perspectives from USA, Canada, Australia, Germany and Japan*: September 2021: virtual, international audience

Chairman, *A Study and discussion of Secondary Progressive MS*,  
Co-Chair with Aaron Boster, MD: September 2021: virtual, national audience

Chairman, "The Cascade Effect: The Role of Complement in NMOSD,"  
PACTRIMS International Symposium; Singapore City, Singapore: 15 Nov 2019

Invited faculty, *Multiple Sclerosis Update*,  
Stanford University Department of Medicine, Grand Rounds; Stanford, CA: 06 Nov 2019

Keynote Speaker, *The Immunopathology of Neuromyelitis Optica Spectrum Disorders*,  
International NMOSD Consortium, Athens Greece: 10 Mar 2019

Invited Faculty, *Drivers of first line treatment decisions*,  
Neuroscience Beyond 2020 Symposium, Munich, Germany; 26 May 2018

### **SPONSORED CLINICAL RESEARCH/ CLINICAL TRIALS (active):**

Principal Investigator and Protocol Director,  
A Phase 1, Open-Label, Single Center Study of KYV-101, an Autologous Fully-Human Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects with Non-Relapsing and

Progressive Forms of Multiple Sclerosis. Clinicaltrials.gov identifier NCT06138132. Protocol ID#: SPO-304838 (XBYE). Sponsor Kyverna Therapeutics, Inc. Protocol 70408.: IRB approved 13 Feb 2024. Active, enrolling.

Protocol Director,

A single arm, open label, Phase 1 study to determine the safety, tolerability, and preliminary efficacy of Obe-cel in participants with refractory progressive forms of Multiple Sclerosis. Stanford ID: IRB-83159. October 2025-present.

Principal Investigator,

A Multicenter Randomized Controlled Trial of best available therapy versus autologous hematopoietic stem cell transplant for treatment-resistant relapsing Multiple Sclerosis. Protocol ITN077AI. Sponsor Immune Tolerance Network and the NIH/National Institute of Allergy and Infectious Disease (NIAID). clinicaltrials.gov identifier NCT04047628. SPO-222791 (XYBE). Active, enrolling, August 2022-present

Principal Investigator,

Project BIG: The Brain, Immune and Gut Research Initiative; Protocol # 36061. IRB approval 2018-present. Sponsor: Project BIG Fund and The Garrett Immunology Research Fund. Active-enrolling: 2018-present

Principal Investigator,

Open Label Extension OLERO Study for longitudinal safety monitoring following a Randomized, Double-Blind, Double Dummy, Parallel-Group Study To Evaluate the Efficacy and Safety Of Ocrelizumab In Comparison To Interferon Beta-1a; Sponsor Genentech: 31 May 2012- 30 June 2027

Co-Investigator,

A Multicenter Phase 1 Study of Allogeneic Hematopoietic Cell Transplantation for Primary Progressive Multiple Sclerosis Using Orca-Q, an Engineered Donor Graft Derived from Mobilized Peripheral Blood; sponsor Orca-Bio; submitted to IRB June 2024, site selected; enrollment pending

Investigator,

Deciphering the role of Epstein-Barr Virus molecular mimicry and B cell transformation in Multiple Sclerosis. Protocol # IRB-12736 Sponsor US Department of Defense, Protocol Director: Bill Robinson, MD: 2023-present

Co-Investigator,

Correlative science study of patients with autoimmune disorders undergoing standard or care pharmaceutical or cell therapy interventions. Protocol PR985101. Sponsor Kyvernatx. PI Everett Meyer SPO # 309911: August 2023-present

Investigator,

A Phase 1/2 Study to Evaluate the Safety, Pharmacokinetics and Biodistribution of an Imaging agent, 18F-OP-801 (18F Hydroxyl Dendrimer), After Intravenous Administration to Patients with Amyotrophic Lateral Sclerosis (ALS) and Healthy Volunteers (HV). Protocol SPO-271594. PI Farshad Moradi. Sponsor Ashvattha Therapeutics: February 2024-present

Co-Investigator,

Structural Characterization of Autoantibodies against Proteolipid Protein in Autoimmune Demyelinating Diseases. Protocol SPO # 302060. Sponsor: Stanford ChEM-H, with Tobias Lanz and the Institute for Immunity & Transplantation: July 2023-present

Investigator,

Analyzing EBV Genomes and Epigenomes and EBV-Dependent B cell Proteomes to Identify Fundamental Viral Triggers of Multiple Sclerosis (MS). IRB- 69705  
Protocol Director: Tobias Lanz : March 2024-present

Co-Investigator,

Anti-Lipid Autoimmunity in Multiple Sclerosis. Protocol SQL 95920.  
Stanford University IRB-12736; Protocol Director Bill Robinson: July 2022-present

Co-Investigator,

KIR and HLA effects in CNS paraneoplastic syndromes and related neuroimmune conditions, (E. Mignot, PI): Stanford SPO # 163059, Sponsor National Institutes of Health NIH, 2021-present

Co-Investigator,

Developing highly innovative methods to measure small intestinal mucosal inflammation and gut permeability in autoimmune diseases SPO # 325507. Proposal: PR1007613: (D. Relman PI: Infectious Disease). Sponsor: Stanford ChEM-H. 2023-present

Investigator,

Beyond ganglion cells: novel foveal avascular zone features in MS with implications for vision loss. Stanford IRB-67401; Protocol Director Heather Moss, MD, PhD: August 2023- present

Investigator,

Analysis of antibodies and immune responses in demyelinating disease (in collaboration with Bill Robinson, MD, PhD): ID: IRB-34529; 2015-present

Sub-Investigator,

High Dimensional Analysis of Immune Subsets with Mass Cytometry and Multiparameter Flow Cytometry in Patients with Secondary Progressive Multiple Sclerosis Treated with Siponimod (L.Steinman, PI): Stanford eProtocol #59039

Investigator,

Ozanimod (Zeposia) in Multiple Sclerosis and Ulcerative Colitis: High Dimensional Immunometabolomic Analysis of Immune Cell Subsets with CyToF, CITE-seq, and Multiparameter Flow Cytometry In Treated Individuals Compared with Baseline. Protocol Director: Lawrence Steinman  
Stanford Protocol ID IRB-68389

### **Sponsored Clinical Research/ Clinical Trials (Past or Completed):**

Principal Investigator,

A Phase 2, Open-Label, Randomized, Multicenter Study of KYV-101, an Autologous Fully Human Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects with Refractory Primary and Secondary Progressive Multiple Sclerosis (KYSA-7): enrollment deferred, pending. September 2024-February 2025.

Investigator,

7T MRI Characterization of Cognitive Assessment of Multiple Sclerosis and Demyelinating Diseases; ID # IRB-30481 Stanford University: August 2017-2024

Principal Investigator, NARCRMS

Toward the Development of a National Longitudinal Data Base in Multiple Sclerosis. Sponsor: The Consortium of Multiple Sclerosis Centers (CMSC): 08/01/2017-16 Aug 2023

Principal Investigator,

A Randomized, Double-Blind, Double Dummy, Parallel-Group Study To Evaluate the Efficacy and Safety Of Ocrelizumab In Comparison To Interferon Beta-1a; Genentech: 31 May 2012- 30 June 2023.

Principal Investigator,

Multicenter, randomized, double blind parallel group extension to study AC-058B202 to Investigate the long term safety, tolerability, and efficacy of 10, 20 and 40 mg/day ACT-128800 (Ponesimod), an oral S1P1 receptor agonist, in patients with relapsing remitting Multiple Sclerosis; Sponsor Actelion: 19 Feb 2010-2021

Protocol Director,

Immune Modulation by Alemtuzumab in Multiple Sclerosis (in collaboration with Wendy Gilmore, PhD; USC; Los Angeles, CA): Stanford Protocol # 16988; 10/09-2019

Protocol Director,

Immunogenetics Studies in Multiple Sclerosis: Vitamin D Protocol  
Protocol IRB-25223: Sponsor NIH 2016-2018

Principal Investigator,

VIDAMS: Vitamin D to ameliorate MS Trial: in collaboration with Johns Hopkins University (Study PI Ellen Mowry, MD) and NIH: 2012-2018

Protocol Director,

Lymphocyte subset analysis of dimethyl fumarate associated lymphopenia; Stanford expedited protocol # 34592: 17 July 2015- 30 June 2018

Principal Investigator;

An open label extension study of safety and tolerability of intravenous alemtuzumab (Lemtrada) in patients with relapsing-remitting Multiple Sclerosis who have relapsed on therapy; extension study of Protocol # CAMMS32400597; Sponsor Genzyme Corporation; Cambridge, MA: 01 Nov 2011-01 Nov 2014

Principal Investigator;

A Phase III Randomized, Rater and Dose Blinded Study Comparing Two Annual Cycles of Intravenous Alemtuzumab to Three Times weekly Subcutaneous Interferon Beta-1a in Patients with Relapsing Remitting Multiple Sclerosis who have Relapsed on Therapy; Protocol CAMMS32400597; Sponsor Genzyme Corporation; Cambridge, MA; Stanford Protocol # 16988: 08 May 2009-07 May 2012

Protocol Director,

Understanding Participation of Racial and Ethnic Groups in Multiple Sclerosis Clinical Trials; Stanford IRB Protocol # 29294: 07 March 2014-28 Feb 2015

Principal Investigator,

Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-finding Study to Evaluate the Efficacy, Safety and Tolerability of Three Doses of ACT-128800 (Ponesimod), an Oral S1P1 Receptor Agonist, Administered for Twenty-four Weeks in Patients with Relapsing-remitting Multiple Sclerosis; Sponsor Actelion: 7 Dec 2010-6 Dec 2012

Co-Investigator,

The Neuroanatomy of Pseudobulbar Affect (in collaboration with Josef Parvizi, MD, PhD; Stanford University; Stanford, CA): Stanford Protocol # 15264; 7/09-2012

Investigator,

JC Virus Antibody Program in Patients with Relapsing Multiple Sclerosis Receiving or Considering Treatment with Natalizumab: The STRATIFY-2 Study. Stanford Protocol #18841; Sponsor Biogen-Idec: 14 June 2011-31 May 2012

Co-Principal Investigator and Protocol Director,

Protocol Title: A Longitudinal, Case-Control Study to Collect Medical and Epidemiological Data and Blood Samples for Research Into the Causes of Multiple Sclerosis and Selected Demyelinating Diseases; Sponsor: Accelerated Cure Project; Stanford Protocol 17667: 01 Mar 2010-July 2013

Principal Investigator;

A Multi-Center, Double Blind, Randomized Study, Comparing the Combined Use of Interferon Beta 1a and Glatiramer Acetate to Either Agent Alone in Patients with Relapsing Remitting Multiple Sclerosis; CombiRx Protocol, Sponsor NIH; Bethesda, MD; September 2005-February 2008

Principal Investigator;

A Multi-Center, Randomized, Double Blinded, Placebo Controlled Study of Subcutaneous Tovaxin in Subjects with Clinically Isolated Syndrome or Relapsing Remitting Multiple Sclerosis: The TERMS Study. Sponsor Opexa Therapeutics; The Woodlands, Texas: November 2006-February 2008

Sub-Investigator;

A Double Blind, Randomized Multicenter Placebo Controlled Parallel Group Study Comparing Efficacy and Safety of FTY720 (Fingolimod) Administered Orally Versus Placebo in Patients with Relapsing Remitting Multiple Sclerosis; Sponsor Novartis Pharma AG; Switzerland; October 2007-February 2008

Sub-Investigator;

Open Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR in Patients with Multiple Sclerosis who Participated in the MS-F204 Trial; Acorda Therapeutics; November 2007-February 2008

Principal Investigator;

A Phase II Randomized, Double Blinded, Placebo Controlled, Multi-Center Dose Ranging Study of Subcutaneous Daclizumab in Patients with Active Relapsing Forms of Multiple Sclerosis; Protocol DAC-1012 CHOICE Study; Sponsor PDL Biopharma; October 2005-November 2007

Sub-Investigator;

Phase I, Double Blind Placebo Controlled, Dose Escalation Study of the Safety of RTL1000 in Subjects with Relapsing Remitting Multiple Sclerosis or Secondary Progressive Multiple Sclerosis; Sponsor Artielle Immunotherapeutics, Inc.; Tigard, Oregon; May 2007-February 2008

Principal Investigator;

A Multi-Center, Randomized, Double Blind, Parallel Group Study to Evaluate the Efficacy, Tolerability, and Safety of 40 mg Glatiramer Acetate in the Treatment of Relapsing Remitting Multiple Sclerosis Patients; Protocol # 9006; Sponsor Teva Neuroscience; 7/04-11/05

Principal Investigator;

A Multi-Center, Randomized Double Blind Parallel Group Study to Evaluate the Safety and Tolerability of Natalizumab in Subjects with Multiple Sclerosis Who Have Completed Studies C-1801, C-1802 and C-1803; Protocol # C-1808; Sponsor Biogen-Idec; Cambridge, MA; 7/04-10/05

Principal Investigator;

A Multi-Centered Two Arm, Open Label Study to Evaluate the Safety, Tolerability and Efficacy of Induction Treatment with Mitoxantrone (Novantrone) Preceding Treatment with Glatiramer Acetate versus Chronic Treatment with Glatiramer Acetate Alone in Relapsing Forms of Multiple Sclerosis; Protocol #NC-100; Sponsor Teva Neuroscience; North Wales, PA; 8/04-2/06

Principal Investigator;

A Retrospective Study to Evaluate the Safety and Tolerability of Copaxone for Injection in Pediatric patients with Relapsing Remitting Multiple Sclerosis; Protocol # PM012; Sponsor Teva Neuroscience; North Wales, PA; 8/04-3/05

Sub-Investigator;

A Double Blind, Placebo Controlled 13 Week Parallel Group Study to Evaluate the Efficacy, Safety and Activity of Oral Fampridine-SR in Subjects with Multiple Sclerosis; Protocol # MS-F301; Sponsor Acorda Therapeutics; Hawthorne, NY; 6/04-2/08

Principal Investigator;

A Phase IV Study of Copolymer I in the Treatment of Multiple Sclerosis; Protocol Cop-I; Sponsor Teva Marion Partners; Kansas City, MO; 1994-1996

### **Inventions and Intellectual Property:**

Inventor,

Marker for determination of patient responsiveness; **Dunn, J.**, Axtell R., Schubert R.  
Developed a test that measures transitional B cells in peripheral blood for use in determining patient responsiveness to Multiple Sclerosis (MS) treatments. United States Patent & Trademark Office patent # 10054588; issue date 21 Aug 2018

### **Post-degree Honors and Awards:**

- *Science* Breakthrough of the Year runner-up, American Association for the Advancement of Science, for the use of CAR-T immunotherapy for MS and neuroimmune disease: February 2025
- Excellence in Bedside Medicine Endowed Lectureship, Johns Hopkins University Department of Medicine; March 2025

- Kaiser Family Foundation Award for Excellence in Teaching Clinical Medicine: February 2025
- Top Doctors as chosen by their peers, *San Francisco Magazine*: May 2024
- Top Docs 2024: national, peer-elected: CastleConnolly.com: 2024
- Certificate of Special Congressional Recognition, United States Congress (CA-04): 2023
- Neurology Clerkship Teaching Award, Stanford University Neurology (2022-2023)
- *Science* Breakthrough of the Year, runner-up, American Association for the Advancement of Science, for demonstrating the association of EBV to Multiple Sclerosis: February 2022
- Oscar Salvatierra Award for Exceptional Service to Medical Students and the School of Medicine, Stanford University School of Medicine (2021)
- Neurology Clerkship Teaching Award, Stanford University Neurology (2019-2020)
- A. B. Baker National Teacher of the Year Recognition Award, American Academy of Neurology (2019)
- Healthcare Partner of the Year, National Multiple Sclerosis Society, NorCal (2019)
- Arthur L. Bloomfield Award in Recognition of Excellence in Teaching Clinical Medicine, Stanford University School of Medicine (2017)
- Special Commendation for outstanding care, research and contributions to the MS community, California State Senate (2016)
- Henry J. Kaiser Family Foundation Award for Excellence in Clinical Teaching, Stanford University School of Medicine (2013)
- Top Doctors: the top doctors in the US as nominated by their peers, Castle Connolly (2012-2023 inclusive)
- AUPN Neurology highest percentage National Recruitment Award, Association of University Professors of Neurology (2012, 2011)
- Excellence in Teaching Award, Stanford University School of Medicine: 2011-2012
- Arthur L. Bloomfield Award in Recognition of Excellence in the Teaching of Clinical Medicine, Stanford University School of Medicine: 2011
- Excellence in Teaching Award, Stanford University School of Medicine: 2010-2011
- Excellence in Teaching Award, Stanford University School of Medicine: 2009-2010
- Fellow, American Academy of Neurology: 2008-present
- Excellence in Neurology Clerkship Teaching Award, Stanford University Neurology: 2008-2017 all years inclusive
- Lysia K. Forno Award for Excellence in Teaching Neurology Residents, Stanford University Department of Neurology & Neurosciences: 2009
- America's Top Rated Physicians, Guide to Top Doctors: 1998-2007 all years inclusive
- Finalist, Pacific Northwest Writers' Association for best screenplay: 2005
- Seattle's Top Doctors for Women, *Seattle Magazine*: 2004
- Subject of biographical inclusion, *Who's Who in America*

**Philanthropy and Community Service:**

Orphan Outreach,  
Charitable medical care to children orphaned by the African AIDS crisis: Mathare slums outside Nairobi,  
Kenya; and Bungoma, Kenya: July 2017: [www.orphanoutreach.org](http://www.orphanoutreach.org)

Buck/Cardinal Club, Stanford University: To help Stanford Athletics field 36 top-level varsity sports  
teams and support student athletes; Stanford University Department of Athletics; Stanford, CA: 2013-  
present

Charter Hill Society, UC Berkeley  
For extraordinary commitment to preserving and enhancing excellence in education;  
UC Berkeley; Berkeley, CA: 2011-2015